Benzinga | Jan 5, 2021 07:27AM EST

B of A Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $47

B of A Securities analyst Tazeen Ahmad initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and announces Price Target of $47.